40% recovery: 4DMedical share price (ASX:4DX) turns sharply and delivers the goods

4DMedical caught bids this week and finished on top.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Investors are bidding up the 4DMedical share price hard this week after a key announcement
  • The launch of the company's XV Scanner is a key driver to the commercialisation of its XV Technology strategy, it says
  • In the last 12 months, the 4DMedical share price has sunk by 44%

The 4DMedical Ltd (ASX: 4DX) share price climbed higher on Friday afternoon to close up 1.18% at 85.5 cents.

Investors appear to be rallying behind Thursday's announcement, which revealed the company is launching the world's first dedicated lung scanner.

The 4DMedical share price soared almost 20% yesterday. It's likely that momentum spilled over into today's session as trading volume surged well past its four-week average at 764,665 shares.

With big gains also on Tuesday and Wednesday, it means 4DMedical shares have surged 41% since last Friday's close. This week's gain is a welcome reprieve for 4D shareholders, who've seen their holdings evaporate over the past 12 months.

TradingView Chart
rising medical asx share price represented by excited doctors dancing in ward

Image source: Getty Images

What's been happening at 4DMedical?

The company advised that it has installed the 'XV Scanner' at the Prince of Wales Hospital in Sydney after it was unveiled to the Federal health minister on Thursday.

4D says the scanner will provide unparalleled access to visually map the lung and provides "highly visual insight into lung function".

A successful launch will hopefully see the market adopt its XV Technology, something the company says is integral to successful commercialisation.

But the benefits extend primarily to the doctor-patient realm, and the scanner itself is considered somewhat a "breakthrough in innovation", according to Lung Foundation Australia CEO, Mark Brooke.

It's reported that seven million Australian currently are living with or are impacted by lung disease in some way, therefore any breakthrough would be a welcome sigh of relief to many.

Evans and Partners have 4DMedical rated as a speculative buy and value the company at $1.50 per share, suggesting an upside potential of 75% at the time of writing.

Meanwhile, Bell Potter has the company rated as a speculative hold but sets a price target of $2.07 per share — a mammoth 142% upside potential.

According to Bloomberg data, the consensus valuation is $1.78 per share, still a considerable amount of upside potential if the bull case plays out to that level.

4DMedical share price snapshot

In the last 12 months, the 4DMedical share price has sunk and is now 44% in the red. It is also down 36% this year to date.

Despite the 40% gain this week, shares have still fallen into the red by 5% over the past month.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two scientists looking at a tablet.
ASX Share Market News

Where will CSL shares be in 12 months? Brokers weigh in

Analysts remain divided over CSL’s recovery prospects.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Why this ASX healthcare share is a retiree's dream for FY27

This defensive business is giving investors rising dividends.

Read more »

Two scientists analysing results on a computer screen.
Broker Notes

Up 88%! Why CSL shares remain an 'appealing' buy today

A top analyst forecasts more outperformance from CSL’s surging shares.

Read more »

Two scientists analysing results on a computer screen.
Earnings Results

Monash IVF Group earnings: FY26 profit slips, outlook improves

The company posted weaker FY26 profit but ends year with improving momentum, dividend, and outlook for growth.

Read more »

Happy investor on tablet with finance graphs rising in overlay.
Healthcare Shares

Bell Potter says this ASX healthcare share could rise 200%+

The broker has good things to say about this growing stock.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

4DMedical share price rises as FY26 revenue climbs, losses moderate

4DMedical lifted revenue 21% and improved its adjusted net loss for FY26, while investing in new AI-driven medical imaging solutions.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Imricor Medical Systems and Philips launch MR-guided cardiac interventions lab

Imricor Medical Systems has teamed up with Philips to launch a new MR-guided cardiac interventions lab, targeting broader clinical adoption.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Why now is the time to buy low on these ASX healthcare shares with up to 84% upside

These two stocks have big upside.

Read more »